These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 16186073)

  • 1. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
    Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response.
    Silvestri A; Gebara O; Vitale C; Wajngarten M; Leonardo F; Ramires JA; Fini M; Mercuro G; Rosano GM
    Circulation; 2003 Jul; 107(25):3165-9. PubMed ID: 12796135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
    Høibraaten E; Qvigstad E; Andersen TO; Mowinckel MC; Sandset PM
    Thromb Haemost; 2001 May; 85(5):775-81. PubMed ID: 11372667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol.
    Blumenfeld Z; Boulman N; Leiba R; Siegler E; Shachar S; Linn R; Levy Y
    Scand J Clin Lab Invest; 2007; 67(3):257-63. PubMed ID: 17454839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of postmenopausal hormone replacement therapy on body fat composition.
    Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
    Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women.
    Rachoń D; Suchecka-Rachoń K; Hak Ł; Myśliwska J
    Menopause; 2006; 13(5):840-5. PubMed ID: 16894332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
    Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women.
    Sumino H; Ichikawa S; Ohyama Y; Takahashi T; Saito Y; Nakamura T; Kanda T; Kurabayashi M
    Am J Cardiol; 2005 Jul; 96(1):148-53. PubMed ID: 15979455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein--a cross-sectional population survey.
    Lowe GD; Upton MN; Rumley A; McConnachie A; O'Reilly DS; Watt GC
    Thromb Haemost; 2001 Aug; 86(2):550-6. PubMed ID: 11522002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of effects of sequential transdermal administration versus oral administration of estradiol plus norethisterone acetate on serum NO levels in postmenopausal women.
    Kurtay G; Ozmen B; Erguder I
    Maturitas; 2006 Jan; 53(1):32-8. PubMed ID: 16325022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease.
    Seljeflot I; Arnesen H; Hofstad AE; Os I
    Thromb Haemost; 2000 Jun; 83(6):944-8. PubMed ID: 10896253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women.
    D'Anna R; Baviera G; Corrado F; Cancellieri F; Crisafulli A; Squadrito F
    Acta Obstet Gynecol Scand; 2005 May; 84(5):474-7. PubMed ID: 15842212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women.
    Cacciatore B; Paakkari I; Hasselblatt R; Nieminen MS; Toivonen J; Tikkanen MI; Ylikorkala O
    Am J Obstet Gynecol; 2001 Apr; 184(5):904-9. PubMed ID: 11303197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?
    McKenzie J; Jaap AJ; Gallacher S; Kelly A; Crawford L; Greer IA; Rumley A; Petrie JR; Lowe GD; Paterson K; Sattar N
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):682-9. PubMed ID: 14974908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk.
    Vitale C; Gebara O; Mercuro G; Wajngarten M; Silvestri A; Rossini P; Ramires JA; Fini M; Rosano GM
    Maturitas; 2005 Apr; 50(4):239-46. PubMed ID: 15780522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral and transdermal hormone replacement therapy on internal carotid artery pulsatility indices in postmenopausal women. A prospective, randomized, comparative study.
    Sendağ F; Terek MC; Karadadaş N; Bilgin O
    J Reprod Med; 2001 Nov; 46(11):962-8. PubMed ID: 11762152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.